1
|
Ali Arazeem A, Tahirah Adedolapo I, Joseph Alabi O. Shame, stigma, and social exclusion: The lived experiences of epileptic patients in a health facility in Ilorin, Nigeria. Glob Public Health 2022; 17:3839-3852. [PMID: 35748774 DOI: 10.1080/17441692.2022.2092174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
BACKGROUND The highest number of persons living with epilepsy (PLWE) are in Africa and the majority live in deplorable conditions, while dealing with varying layers of stigma, social exclusion, and discrimination. OBJECTIVE This study explored the lived experiences of PLWE in Ilorin. METHODS Adopting a qualitative design and a phenomenological lens, 10 PLWE between the ages of 18 and 60 were purposively selected from the University of Ilorin Teaching Hospital (UITH) for in-depth interviews. RESULTS Findings suggest that PLWE bear multiple and intersecting burdens, including physical injuries; institutional, cultural, and economic constraints; psychological strain; social exclusion; and stigma. These disadvantages are often sustained and reproduced by various assumptions about epilepsy; as such, PLWE conceal their condition, and this implicatively reinforce stigma. Difficulty sustaining intimate relationships, overt physical scars, and inferiority complexes are recurrent challenges for PLWE. The study showed that adherence to drugs, self-management, personal precautions towards seizure signs, and family support are important coping strategies. CONCLUSION The study recommends that it is imperative to enhance and sustain systems, processes, and attitudes that prioritise the physical, social, and emotional needs of PLWE, because this is significant for their enhanced quality of life (QoL).
Collapse
Affiliation(s)
- Abdullahi Ali Arazeem
- Department of Sociology, University of Johannesburg, Gauteng, South Africa.,Department of Democracy and Governance, National Institute for Legislative and Democratic Studies, Abuja, Nigeria
| | | | | |
Collapse
|
2
|
Why won't it stop? The dynamics of benzodiazepine resistance in status epilepticus. Nat Rev Neurol 2022; 18:428-441. [PMID: 35538233 DOI: 10.1038/s41582-022-00664-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2022] [Indexed: 11/08/2022]
Abstract
Status epilepticus is a life-threatening neurological emergency that affects both adults and children. Approximately 36% of episodes of status epilepticus do not respond to the current preferred first-line treatment, benzodiazepines. The proportion of episodes that are refractory to benzodiazepines is higher in low-income and middle-income countries (LMICs) than in high-income countries (HICs). Evidence suggests that longer episodes of status epilepticus alter brain physiology, thereby contributing to the emergence of benzodiazepine resistance. Such changes include alterations in GABAA receptor function and in the transmembrane gradient for chloride, both of which erode the ability of benzodiazepines to enhance inhibitory synaptic signalling. Often, current management guidelines for status epilepticus do not account for these duration-related changes in pathophysiology, which might differentially impact individuals in LMICs, where the average time taken to reach medical attention is longer than in HICs. In this Perspective article, we aim to combine clinical insights and the latest evidence from basic science to inspire a new, context-specific approach to efficiently managing status epilepticus.
Collapse
|
3
|
Pironi V, Ciccone O, Beghi E, Paragua-Zuellig H, Patel AA, Giussani G, Bianchi E, Venegas V, Vigevano F. Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment. Epilepsia 2022; 63:335-351. [PMID: 34981508 DOI: 10.1111/epi.17155] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 12/05/2021] [Accepted: 12/09/2021] [Indexed: 11/30/2022]
Abstract
Health systems worldwide are challenged in the provision of basic medical services and access to treatments for chronic conditions. Epilepsy, the most common severe chronic neurological disorder, does not receive sufficient attention despite being officially declared a public health priority by the World Health Organization. More than 80% of people with epilepsy live in middle- and low-income countries (MICs and LICs, respectively), where most of the population lacks reliable access to antiseizure medications (ASMs), contributing significantly to the large epilepsy treatment gap in these regions. The International League Against Epilepsy (ILAE) Task Force on Access to Treatment administered a global survey to report on the current access to ASMs worldwide. The survey was developed and distributed online through the ILAE and International Bureau of Epilepsy (IBE) secretariats to the chapter representatives. The survey was completed by one representative per country. Response rate was 73.2% (101 countries of the 138 represented in ILAE and/or IBE organizations). Availability and access of ASMs, including distribution problems and costs, reimbursement procedures, general barriers to access to care, and presence of projects targeted toward improving care access, were studied, and descriptive statistics on available responses were performed. Among the 15 first-generation ASMs surveyed, carbamazepine was reported as the most widely available globally. At least one first-generation ASM is widely available in most countries, but their number differs dramatically across income levels. Second- and third-generation ASMs are even more limited in MICs and LICs. Additionally, average retail prices for ASMs were not significantly different across countries despite the differences in per capita income from high-income countries to LICs. This survey provides a worrisome picture of availability and accessibility of ASMs across the world, with wide disparities according to socioeconomic status. Recommendations for direct action on improving access to care will be discussed.
Collapse
Affiliation(s)
- Virginia Pironi
- Center for Rare Diseases and Birth Defects, Department of Woman and Child Health, Institute of Pediatrics, A. Gemelli University Polyclinic Foundation, Scientific Institute for Research and Health Care, Catholic University of Rome, Rome, Italy.,Child Neurology and Psychiatry Unit, AUSL della Romagna, Ravenna, Italy
| | - Ornella Ciccone
- University Teaching Hospitals, Children's Hospital, Lusaka, Zambia.,Istituto Serafico di Assisi, Assisi, Italy
| | - Ettore Beghi
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Scientific Institute for Research and Health Care, Milan, Italy
| | - Hazel Paragua-Zuellig
- University of the Philippines Manila College of Public Health, Manila, Philippines.,Brain Institute, Cardinal Santos Medical Center, Manila, Philippines.,San Beda University College of Medicine, Manila, Philippines
| | - Archana A Patel
- Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Giorgia Giussani
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Scientific Institute for Research and Health Care, Milan, Italy
| | - Elisa Bianchi
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Scientific Institute for Research and Health Care, Milan, Italy
| | - Viviana Venegas
- Unit of Pediatric Neurology, Advanced Center of Epilepsy, Clinica Alemana de Santiago, Vitacura, Chile.,Unit of Neurophysiology, Istituto de Neurocirugia Asenjo, Santiago, Chile
| | - Federico Vigevano
- Neuroscience Department, Bambino Gesù Children's Hospital, Scientific Institute for Research and Health Care, Full Member of European Reference Network EpiCARE, Rome, Italy
| | | |
Collapse
|
4
|
Sengxeu N, Dufat H, Boumediene F, Vorachit S, Chivorakoun P, Souvong V, Manithip C, Preux P, Ratsimbazafy V, Jost J. Availability, affordability, and quality of essential antiepileptic drugs in Lao PDR. Epilepsia Open 2020; 5:550-561. [PMID: 33336126 PMCID: PMC7733656 DOI: 10.1002/epi4.12432] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 08/19/2020] [Accepted: 08/27/2020] [Indexed: 11/18/2022] Open
Abstract
OBJECTIVE Epilepsy is a chronic condition treatable by cost-effective antiepileptic drugs (AEDs), but limited access to treatment was documented. The availability and affordability of good quality of AEDs play a significant role in access to good health care. This study aimed to assess the availability, affordability, and quality of long-term AEDs in Lao PDR. METHOD A cross-sectional study was performed in both public and private drug supply chains in urban and rural areas in Lao PDR. Data on AEDs availability and price were obtained through drug suppliers. Affordability was estimated as the number of day wages the lowest-paid government employee must work to purchase a monthly treatment. Samples of AEDs were collected, and the quality of AEDs was assessed through Medicine Quality Assessment Reporting Guidelines. RESULTS Out of 237 outlets visited, only 50 outlets (21.1% [95% CI 16.1-26.8]) had at least one AED available. The availability was significantly different between urban (24.9%) and rural areas (10.0%), P = .017. Phenobarbital 100 mg was the most available (14.3%); followed by sodium valproate 200 mg (9.7%), phenytoin 100 mg (9.7%), and carbamazepine 200 mg (8.9%). In provincial/district hospitals and health centers, AEDs were provided free of charge. In other healthcare facilities, phenytoin 100 mg and phenobarbital 100 mg showed the best affordability (1.0 and 1.2 day wages, respectively) compared to carbamazepine 200 mg (2.3 days) and other AEDs. No sample was identified as counterfeit, but 15.0% [95% CI 7.1-26.6] of samples were classified as of poor quality. SIGNIFICANCE We quantified and qualified the various factors contributing to the high treatment gap in Lao PDR, adding to diagnostic issues (not assessed here). Availability remains very low and phenobarbital which is the most available and affordable AED was the worst in terms of quality. A drug policy addressing epilepsy treatment gap would reduce these barriers.
Collapse
Affiliation(s)
- Noudy Sengxeu
- INSERMUniv. Limoges, CHU LimogesIRDU1094 Tropical NeuroepidemiologyInstitute of Epidemiology and Tropical NeurologyGEISTLimogesFrance
- Faculty of pharmacyUniversity of Health sciencesVientianeLao PDR
| | - Hanh Dufat
- Natural Products, Analysis and SynthesisCiTCoM‐UMR 8038 CNRS/Université de Paris, Faculty of Health‐Pharmacy, Université de ParisParisFrance
| | - Farid Boumediene
- INSERMUniv. Limoges, CHU LimogesIRDU1094 Tropical NeuroepidemiologyInstitute of Epidemiology and Tropical NeurologyGEISTLimogesFrance
| | | | | | | | | | - Pierre‐Marie Preux
- INSERMUniv. Limoges, CHU LimogesIRDU1094 Tropical NeuroepidemiologyInstitute of Epidemiology and Tropical NeurologyGEISTLimogesFrance
| | - Voa Ratsimbazafy
- INSERMUniv. Limoges, CHU LimogesIRDU1094 Tropical NeuroepidemiologyInstitute of Epidemiology and Tropical NeurologyGEISTLimogesFrance
| | - Jeremy Jost
- INSERMUniv. Limoges, CHU LimogesIRDU1094 Tropical NeuroepidemiologyInstitute of Epidemiology and Tropical NeurologyGEISTLimogesFrance
| |
Collapse
|
5
|
Medication Beliefs and Adherence to Antiseizure Medications. Neurol Res Int 2020; 2020:6718915. [PMID: 33163231 PMCID: PMC7604606 DOI: 10.1155/2020/6718915] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 09/01/2020] [Accepted: 09/30/2020] [Indexed: 11/23/2022] Open
Abstract
Introduction The primary objective of our study was to determine the nature of medication beliefs and their association with adherence to antiseizure medications (ASMs) among elderly epilepsy patients. Our secondary objective was to enhance the psychometric properties and factor structure parameters of the Beliefs about Medications Questionnaire (BMQ) adapted to epilepsy and affected aged subjects. Methods A population-based survey was performed in which older adults (≥60 years of age) were invited for a free face-to-face consultation with the specialists as well as for the collection of necessary data. The eligible subjects were those who are affected with epilepsy and having epileptic seizures of any type. In addition, the participants were required to be of any sex, currently under treatment with ASMs, resident of Tehran, and able and interested to participate independently. All were carefully examined with a reasonably detailed case-history examination. Two Persian questionnaires used were Medication Adherence Rating Scale (MARS) and BMQ. Those with a MARS score of ≥6 were considered as adherent to ASMs. All data were described in descriptive terms. We did a group comparison of means and proportions for all possible independent variables between adherents and nonadherents. Then, we did a hierarchical multiple linear regression. For this, independent variables were categorized into three different blocks: (a) sociodemographic block (Block-1), (b) treatment side-effect block (Block-2), and (c) BMQ block that included ten items of the BMQ scale (Block-3). We also did a forward step-wise linear regression by beginning with an empty model. We also estimated the psychometric properties and factor structure parameters of BMQ and its two subdomains. Results Of all (N = 123, mean age: 63.3 years, 74.0% males), 78.0% were adherent (mean score: 7.0, 95% CI 6.2–7.8) to ASMs. The MARS scores were not different between males and females. The mean BMQ score was 23.4 (95% CI 19.8–27.0) with the mean need score of 20.0 (95% CI 18.0–22.0) and mean concern score of 16.5 (95% CI 14.3–18.7). A positive need-concern differential was 20.4%. Upon hierarchical regression, the adjusted R2 for Block-1 was 33.8%, and it was 53.8% for Block-2 and 92.2% for Block-3. Upon forward step-wise linear regression, we found that “ASMs disrupt my life” (ß −1.9, ES = −1.1, p=0.008) as the only belief associated with adherence. The alpha coefficient of BMQ was 0.81. Conclusions Ours is one of the very few studies that evaluated medication beliefs and their association with adherence to ASMs among elderly epilepsy patients in a non-western context. In our context, medication beliefs are likely to have an independent role in effecting adherence to ASMs, particularly the concern that “ASMs disrupt life.” Treating physicians should cultivate good conscience about ASMs and evaluate the patient's medication beliefs early-on to identify those who might be at the risk of becoming nonadherent.
Collapse
|
6
|
Navis A, Dallah I, Mabeta C, Musukuma K, Siddiqi OK, Bositis CM, Koralnik IJ, Gelbard HA, Theodore WH, Okulicz JF, Johnson BA, Sikazwe I, Bearden DR, Birbeck GL. Evaluating the impact of antiretroviral and antiseizure medication interactions on treatment effectiveness among outpatient clinic attendees with HIV in Zambia. Epilepsia 2020; 61:2705-2711. [PMID: 33084053 DOI: 10.1111/epi.16723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 09/20/2020] [Accepted: 09/22/2020] [Indexed: 01/20/2023]
Abstract
OBJECTIVE Interactions between enzyme-inducing anti-seizure medications (EI-ASMs) and antiretroviral drugs (ARVs) can lead to decreased ARV levels and may increase the likelihood of viral resistance. We conducted a study to determine if co-usage of ARVs and EI-ASMs is associated with ARV-resistant human immunodeficiency virus (HIV) among people living with HIV in Zambia. METHODS Eligible participants were ≥18 years of age and concurrently taking ASMs and ARVs for at least 1 month of the prior 6-month period. Data were obtained regarding medication and HIV history. CD4 counts, plasma viral loads (pVLs), and HIV genotype and resistance profile in participants with a pVL >1000 copies/mL were obtained. Pearson's test of independence was used to determine whether treatment with EI-ASM was associated with pVL >1000/mL copies. RESULTS Of 50 participants, 41 (82%) were taking carbamazepine (37 on monotherapy), and all had stable regimens in the prior 6 months. Among the 13 ARV regimens used, 68% had a tenofovir/lamivudine backbone. The majority (94%) were on a stable ARV regimen for >6 months. Median CD4 nadir was 205 cells/mm3 (interquartile range [IQR] 88-389), and 60% of participants had commenced ARV treatment before advanced disease occurred. Mean CD4 count at enrollment was 464 cells/mm3 (SD 226.3). Seven participants (14%) had a CD4 count <200 cells/mm3 . Four (8%) had a pVL >1000 copies/mL; all were on carbamazepine. Three participants with elevated pVL had a CD4 count <200 cells/mm3 . None had documented adherence concerns by providers; however, two had events concerning for clinical failure. HIV genotype testing showed mutations in three participants. Carbamazepine was not found to correlate with elevated pVL (P = .58). SIGNIFICANCE EI-ASMs are commonly used in sub-Saharan Africa. Despite concurrent use of EI-ASMs and ARVs, the majority of participants showed CD4 counts >200 cells/mm3 and were virally suppressed. Carbamazepine was not associated with an increased risk of virological failure or ARV-resistant HIV.
Collapse
Affiliation(s)
- Allison Navis
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ifunanya Dallah
- Department of Neurology, University of Rochester, Rochester, NY, USA
| | | | - Kalo Musukuma
- University Teaching Hospitals Children's Hospital, Lusaka, Zambia
| | - Omar K Siddiqi
- Global Neurology Program, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.,Department of Internal Medicine, Center for Vaccines and Virology Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.,Department of Internal Medicine, University of Zambia School of Medicine, Lusaka, Zambia
| | | | - Igor J Koralnik
- Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Harris A Gelbard
- Departments of Neurology, Pediatrics, Neuroscience and Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA
| | - William H Theodore
- National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA
| | - Jason F Okulicz
- Infectious Disease Service, Brooke Army Medical Center, Joint Base San Antonio-Ft Sam Houston, Houston, TX, USA
| | - Brent A Johnson
- Department of Biostatistics, Center for AIDS Research, University of Rochester, Rochester, NY, USA
| | - Izukanji Sikazwe
- Center for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia
| | - David R Bearden
- Department of Neurology, University of Rochester, Rochester, NY, USA
| | - Gretchen L Birbeck
- Department of Neurology, University of Rochester, Rochester, NY, USA.,Chikankata Epilepsy Care Team, Mazabuka, Zambia.,University Teaching Hospitals Children's Hospital, Lusaka, Zambia
| |
Collapse
|
7
|
Vitry A, Forte G, White J. Access to Controlled Medicines in Low-Income Countries: Listening to Stakeholders in the Field. INTERNATIONAL JOURNAL OF HEALTH SERVICES 2020; 51:404-411. [PMID: 32098570 DOI: 10.1177/0020731420906748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Little is known on current practices and challenges associated with the legal trade of medicines controlled under international conventions in low-income countries. This qualitative survey involved semi-structured interviews of stakeholders engaged in the trade of controlled medicines at a global level or at a country level in 3 African countries (Uganda, Kenya, Democratic Republic of the Congo). Nine interviews were conducted, including 3 international wholesalers, 2 relief organizations, 2 procurement officers, and 2 regulatory officers. Additionally, 4 other participants provided written information. All participants consistently reported that the current process of procuring controlled medicines in compliance with international conventions was long and complex given the number of administrative steps required for obtaining export and import authorizations, which are mandatory for both narcotic and psychotropic medicines. It may be difficult or impossible to obtain import authorizations from some health authorities in low-income countries because of long delays, mistakes in forms, absence or shortage of staff, or when annual national estimates are exceeded. The complexities of the trade of controlled medicines directly contribute to the lack of access to essential controlled medicines, both narcotics and psychotropics, in low-income countries.
Collapse
Affiliation(s)
- Agnes Vitry
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
| | - Gilles Forte
- Access to Medicines, Vaccines and Pharmaceuticals, World Health Organization, Geneva, Switzerland
| | - Jason White
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia
| |
Collapse
|
8
|
Singh G, Sharma M, Krishnan A, Dua T, d'Aniello F, Manzoni S, Sander JW. Models of community-based primary care for epilepsy in low- and middle-income countries. Neurology 2020; 94:165-175. [PMID: 31919114 DOI: 10.1212/wnl.0000000000008839] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2019] [Accepted: 11/07/2019] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To review systematically community-based primary care interventions for epilepsy in low- and middle-income countries to rationalize approaches and outcome measures in relation to epilepsy care in these countries. METHODS A systematic search of PubMed, EMBASE, Global Index Medicus, CINAHL, and Web of Science was undertaken to identify trials and implementation of provision of antiseizure medications, adherence reinforcement, and/or health care provider or community education in community-based samples of epilepsy. Data on populations addressed, interventions, and outcomes were extracted from eligible articles. RESULTS The 24 reports identified comprise mostly care programs addressing active convulsive epilepsy. Phenobarbital has been used most frequently, although other conventional antiseizure medications (ASMs) have also been used, but none of the newer. Tolerability rates in these studies are high, but overall attrition is considerable. Other approaches include updating primary health care providers, reinforcing treatment adherence in clinics, and raising community awareness. In these programs, the coverage of existing treatment gap in the community, epilepsy-related mortality, and comorbidity burden are only fleetingly addressed. None, however, explicitly describe sustainability plans. CONCLUSIONS Cost-free provision, mostly of phenobarbital, has resulted in short-term seizure freedom in roughly half of the people with epilepsy in low- and middle-income countries. Future programs should include a range of ASMs. These should cover apart from seizure control and treatment adherence, primary health care provider education, community awareness, and referral protocols for specialist care. Programs should incorporate impact assessment at the local level. Sustainability in the long term as much as resilience and scalability should be addressed in future initiatives.
Collapse
Affiliation(s)
- Gagandeep Singh
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands
| | - Meenakshi Sharma
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands
| | - Anand Krishnan
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands
| | - Tarun Dua
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands
| | - Francesco d'Aniello
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands
| | - Sara Manzoni
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands
| | - Josemir W Sander
- From the Department of Neurology (G.S.), Dayanand Medical College, Ludhiana, India; Division of Non-Communicable Diseases (M.S.), Indian Council of Medical Research; Department of Community Medicine (A.K.), All India Institute of Medical Sciences, New Delhi, India; Mental Health Division (T.D.), World Health Organization, Geneva, Switzerland; Department of Clinical Medicine and Surgery (F.d'.A.), University of Naples Federico II, ; University of Campania (S.M.), Luigi Vanvitelli, Naples, Italy; NIHR University College London Hospitals Biomedical Research Centre (G.S., J.W.S.), UCL Queen Square Institute of Neurology, London, Chalfont Centre for Epilepsy (G.S., J.W.S.), Chalfont St Peter, United Kingdom; and Stichting Epilepsie Instellingen Nederland (SEIN) (J.W.S.), Heemstede, Netherlands.
| |
Collapse
|
9
|
Gharagozli K, Lotfalinezhad E, Amini F, Saii V, Bhalla D. Evaluation of Fear in Idiopathic Epilepsy Using Population-Based Survey and Bhalla-Gharagozli Fear in Epilepsy Questionnaire (BG-FEQ). Neuropsychiatr Dis Treat 2020; 16:1685-1693. [PMID: 32764944 PMCID: PMC7360404 DOI: 10.2147/ndt.s248785] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Accepted: 06/28/2020] [Indexed: 12/27/2022] Open
Abstract
INTRODUCTION The primary objective of this study was to evaluate fear related to epilepsy and its treatment among those with idiopathic epilepsy. Our secondary objective was to estimate the psychometric properties of a brief Bhalla-Gharagozli Fear in epilepsy Questionnaire (BG-FEQ). METHODS We conducted patient-finding exercise in our study areas through various means to obtain subjects with idiopathic epilepsy. We carefully examined each patient through a detailed case-history examination. Following that, we evaluated fear related to epilepsy by using Bhalla-Gharagozli Fear in Epilepsy Questionnaire (BG-FEQ) across two broad domains: epilepsy and pharmacotherapy. RESULTS The study obtained 52 subjects (39.0 years; 45.0% males, 70.0% married, 35.0% unqualified, 85.0% active epilepsy, 80.0% generalized seizures) with idiopathic epilepsy. The alpha coefficient was 92.8, with no item-specific coefficient of ≤0.91. The alpha coefficient was 0.90 and 0.93 for reporting a "yes" and "no" to the items, respectively. We obtained a two-factor structure of BG-FEQ that provided a cumulative variance of 83.6%. The majority (65.0%) reported at least one fear. The per-patient mean number of the fear element was 2.1 (95% CI 1.1-3.3), which differed significantly for males and females (1.1, 95% CI 0.4-2.6 and 3.0, 95% CI 1.4-4.6, respectively, p=0.03). The most frequent fear was that of addiction and the bad effects of anti-seizure medications (both 45.0%). Upon bootstrap regression after constraining gender, the fear elements were associated with illiteracy, difficulty in understanding epilepsy and sleeping in a prone position. The sample power was 99.0%. CONCLUSION There was a significant representation of fear among those with idiopathic epilepsy, especially among the females, particularly the fear of brain tumour, premature death and more frequent/severe seizures over time. At least 65.0% of idiopathic subjects are likely to be affected by at least one fear. The essential mitigating approach should be the education of practitioners towards better identification and therapeutic handling of comorbid constructs, and also for the education of patients and their caregivers towards better awareness and prevention. There is also a need for formal Epilepsy Educators towards better awareness, therapeutic support and prevention of epilepsy.
Collapse
Affiliation(s)
- Kurosh Gharagozli
- Iran Epilepsy Association, Tehran, Iran.,Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.,Brain Mapping Research Centre, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Elham Lotfalinezhad
- Department of Health Education and Promotion, Tabriz University of Medical Sciences, Tabriz, Iran.,Iranian Research Centre on Aging, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
| | - Fatemeh Amini
- Iranian Research Centre on Aging, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
| | - Vida Saii
- Iran Epilepsy Association, Tehran, Iran
| | - Devender Bhalla
- Nepal Interest Group of Epilepsy and Neurology (NiGEN), Kathmandu, Nepal.,Sudan League of Epilepsy and Neurology (SLeN), Khartoum, Sudan.,Pôle Universitaire Euclide Intergovernmental UN Treaty 49006/49007, Bangui, Central African Republic
| |
Collapse
|
10
|
Samia P, Hassell J, Hudson JA, Murithi MK, Kariuki SM, Newton CR, Wilmshurst JM. Epilepsy diagnosis and management of children in Kenya: review of current literature. Res Rep Trop Med 2019; 10:91-102. [PMID: 31388319 PMCID: PMC6607977 DOI: 10.2147/rrtm.s201159] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 04/12/2019] [Indexed: 01/04/2023] Open
Abstract
Introduction: The growing impact of non-communicable diseases in low- to middle-income countries makes epilepsy a key research priority. We evaluated peer-reviewed published literature on childhood epilepsy specific to Kenya to identify knowledge gaps and inform future priorities. Methodology: A literature search utilizing the terms "epilepsy" OR "seizure" as exploded subject headings AND "Kenya" was conducted. Relevant databases were searched, generating 908 articles. After initial screening to remove duplications, irrelevant articles, and publications older than 15 years, 154 papers remained for full-article review, which identified 35 publications containing relevant information. Data were extracted from these reports on epidemiology, etiology, clinical features, management, and outcomes. Results: The estimated prevalence of lifetime epilepsy in children was 21-41 per 1,000, while the incidence of active convulsive epilepsy was 39-187 cases per 100,000 children per year. The incidence of acute seizures was 312-879 per 100,000 children per year and neonatal seizures 3,950 per 100,000 live births per year. Common risk factors for both epilepsy and acute seizures included adverse perinatal events, meningitis, malaria, febrile seizures, and family history of epilepsy. Electroencephalography abnormalities were documented in 20%-41% and neurocognitive comorbidities in more than half. Mortality in children admitted with acute seizures was 3%-6%, and neurological sequelae were identified in 31% following convulsive status epilepticus. Only 7%-29% children with epilepsy were on antiseizure medication. Conclusion: Active convulsive epilepsy is a common condition among Kenyan children, remains largely untreated, and leads to extremely poor outcomes. The high proportion of epilepsy attributable to preventable causes, in particular neonatal morbidity, contributes significantly to the lifetime burden of the condition. This review reaffirms the ongoing need for better public awareness of epilepsy as a treatable disease and for national-level action that targets both prevention and management.
Collapse
Affiliation(s)
- Pauline Samia
- Department of Paediatrics and Child Health, Aga Khan University, Nairobi, Kenya
| | - Jane Hassell
- Gertrude’s Children’s Hospital, Child development Centre, Nairobi, Kenya
| | | | | | - Symon M Kariuki
- Kemri–Wellcome Trust Collaborative Programme, Centre for Geographic Medicine Research Programme, Kilifi, Kenya
| | - Charles R Newton
- Kemri–Wellcome Trust Collaborative Programme, Centre for Geographic Medicine Research Programme, Kilifi, Kenya
| | - Jo M Wilmshurst
- Division of Paediatric Neurology, Department of Paediatrics and Child Health, Red Cross War Memorial Children’s Hospital, Neuroscience Institute, University of Cape Town, Rondebosch, South Africa
| |
Collapse
|
11
|
Explanatory factors of adherence to community-based management of epilepsy in Lao PDR. Epilepsy Behav 2018; 88:74-80. [PMID: 30241057 DOI: 10.1016/j.yebeh.2018.08.034] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 08/27/2018] [Accepted: 08/27/2018] [Indexed: 11/21/2022]
Abstract
RELEVANCE A low level of knowledge about epilepsy among health workers, a context of stigmatizing sociocultural beliefs, and a low availability of antiepileptic drugs in Lao People's Democratic Republic (PDR) are major gaps in the medical management of people with epilepsy in this country. OBJECTIVES The principal objective of the study was to identify the associated factors of adherence to community healthcare structures in Lao PDR. Specific objectives were to evaluate patients' adherence status, practices and knowledge about epilepsy and its care, and factors influencing decision-making on therapeutic interventions. MATERIALS AND METHODS The study was an observational cross-sectional survey about knowledge, attitudes, and practices, handled from February to May 2016. Eighty-seven people with epilepsy were identified in two areas in the periphery of Vientiane Capital through an active screening in villages and homes. Semidirective questionnaires were conducted to collect quantitative and qualitative data. Quantitative analysis included a comparison of adherent vs. nonadherent people with epilepsy, using Chi-square or Fisher's test. Advanced qualitative lexical analysis was carried out on the open-ended questions. RESULTS Sixty-two people with epilepsy were included and the adherence rate to community care was 67.7%. The only sociodemographic variable that differed significantly between adherent and nonadherent members was the income level (p = 0.015): the wealthiest class of people with epilepsy did not adhere to community healthcare. Eleven percent of people with epilepsy thought that epilepsy was contagious, 80.6% that medication may reduce epilepsy seizure rates, and 33.9% that it was possible to cure epilepsy permanently. Physicians informed about the disease in 69.0% of adherent people with epilepsy and in 40.0% of nonadherent ones (p = 0.029), whereas villagers were involved in 29.0% and 50.0% of cases, respectively. There was a significant difference between the two groups for the prescribed antiepileptic drugs (p = 0.012): phenobarbital covered 73.8% of adherent people with epilepsy but only 40% of nonadherent ones. Half of nonadherent people with epilepsy went regularly to a central hospital in the Vientiane Capital, 15.0% went to Thailand, and 10.0% practiced self-medication in occasional mobilities. CONCLUSION A wider range of antiepileptic drugs at a reduced cost and the promotion of adherence to community healthcare would allow a better management of people with epilepsy in Lao PDR.
Collapse
|
12
|
Birbeck GL. The forgotten. Neurology 2018. [DOI: 10.1212/wnl.0000000000006386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
13
|
Ciccone O, Chabala C, Tembo O, Mathew M, Grollnek AK, Patel AA, Birbeck GL. A retrospective observational study of EEG findings and antiepileptic drug use among children referred for EEG to Zambia's University Teaching Hospital. Epilepsia Open 2018; 3:503-510. [PMID: 30525119 PMCID: PMC6276775 DOI: 10.1002/epi4.12267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/06/2018] [Indexed: 12/26/2022] Open
Abstract
Objective Despite the heavy burden of epilepsy in Sub‐Saharan Africa, there remains a relative paucity of neurophysiology services and limited published data on electroencephalography (EEG) features among African children. The aim of this study was to describe clinical characteristics, EEG findings, and antiepileptic drug (AED) use among children referred for EEG to the University Teaching Hospital in Zambia. Methods EEG referrals and reports from 2013–2015 were reviewed. Within the context of routine care, EEG studies were interpreted by readers with advanced training in child neurology and clinical neurophysiology. Clinical data provided in the referral including seizure semiology and EEG findings were systematically extracted and analyzed. Results A total of 1,217 EEG reports were reviewed, with 1,187 included in the analysis. Median age was 7 years (interquartile range [IQR] 3–11) and 57% were male. Seventy‐three percent of 554 had documented seizure onset before 5 years of age. Among the 23% with seizure etiology documented, 78% were associated with perinatal injuries and central nervous system (CNS) infections. EEG abnormalities were found in 75% of the studies. Clinical semiology per referral identified focal seizures in 29%, but EEG findings increased this proportion to 63% (p = 0.004). Sixty‐two percent were taking AEDs, with 85% on monotherapy. The most commonly used AED was carbamazepine (49%).There was no association between the choice of AED and clinical semiology (all p's > 0.05). Significance This tertiary care center study identified >60% of referred children to have localization‐related epilepsies, with at least 18% of epilepsies being from potentially preventable causes. These findings are consistent with multi‐country, population‐based data from elsewhere in Africa. Seizure semiology assessed in routine, nonspecialist care does not predict AED choice, and the presence of focality is underestimated in routine care.
Collapse
Affiliation(s)
- Ornella Ciccone
- University Teaching Hospitals Children's Hospital Lusaka Zambia.,University of Zambia School of Medicine Lusaka Zambia
| | - Chishala Chabala
- University Teaching Hospitals Children's Hospital Lusaka Zambia.,University of Zambia School of Medicine Lusaka Zambia
| | - Owen Tembo
- University Teaching Hospitals Children's Hospital Lusaka Zambia
| | - Manoj Mathew
- University Teaching Hospitals Children's Hospital Lusaka Zambia.,University of Zambia School of Medicine Lusaka Zambia
| | | | - Archana A Patel
- Department of Neurology Boston Children's Hospital Boston Massachusetts U.S.A
| | - Gretchen L Birbeck
- Epilepsy Division Department of Neurology University of Rochester Rochester New York U.S.A.,Epilepsy Care Team Chikankata Hospital Mazabuka Zambia
| |
Collapse
|
14
|
Bhalla D. Availability and sufficiency of phenobarbital, an essential medication, in Bhutan: a survey of global and neuropsychiatric relevance. BMC Res Notes 2018; 11:549. [PMID: 30071884 PMCID: PMC6071438 DOI: 10.1186/s13104-018-3617-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2018] [Accepted: 07/19/2018] [Indexed: 12/16/2022] Open
Abstract
Objective We aimed to provide a reliable evidence-based conclusion around manufacturing, import, availability and sufficiency of one essential medication, phenobarbital (PB) through our example location (Bhutan). The relevant details about manufacturing, import, annual quantity, dose strength were obtained. Results There was no local manufacturing of PB and all other anti-seizure medications. A total of 1068 vials of PB 200 mg/mL inj and 489,350 tablets of PB30 mg (i.e. 14.6 kilos) was estimated to annually become available. Of this, 5.3 k (36.3%) was present at the basic health units (BHUs). The PB was absent at 26 (14.7%) BHUs. There was no availability of PB syrup. Treating supposed target of 50.0% of the 20.0% of the prevalent case-load (N = 4523) require 18.1 kilo of PB annually. To conclude, having or not the local manufacturing may or may not be a limitation. There is a need to overcome challenges of inappropriate dose strength, absent pediatric formulation, indirect cost, and low selling price of PB. The possible therapeutic participation of PB in managing disease conditions (like epilepsy) remains limited despite favorable safety and efficacy profile. Strengthening the availability of essential medications is essential to reduce the treatment gap and public health burden of treatable disease conditions.
Collapse
Affiliation(s)
- Devender Bhalla
- Sudan League of epilepsy and Neurology (SLeN), Khartoum, Sudan. .,Nepal Interest Group of Epilepsy and Neurology (NiGEN), Kathmandu, Nepal. .,Iran Epilepsy Association, Teheran, Iran.
| |
Collapse
|
15
|
Medication prescribing and patient-reported outcome measures in people with epilepsy in Bhutan. Epilepsy Behav 2016; 59:122-7. [PMID: 27131914 DOI: 10.1016/j.yebeh.2016.03.035] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/23/2016] [Revised: 03/22/2016] [Accepted: 03/25/2016] [Indexed: 11/23/2022]
Abstract
OBJECTIVE The aim of this study was to assess medication prescribing and patient-reported outcomes among people with epilepsy (PWE) in Bhutan and introduce criteria for evaluating unmet epilepsy care needs, particularly in resource-limited settings. METHODS People with epilepsy in Bhutan (National Referral Hospital, 2014-2015) completed a questionnaire, the Quality of Life in Epilepsy Inventory (QOLIE-31), and an electroencephalogram (EEG). Management gap was the proportion of participants meeting any of six prespecified criteria based on best practices and the National Institute for Health and Care Excellence (NICE) guidelines. RESULTS Among 253 participants (53% female, median: 24years), 93% (n=235) were treated with antiepileptic drugs (AEDs). Seventy-two percent (n=183) had active epilepsy (≥1 seizure in the prior year). At least one criterion was met by 55% (n=138) of participants, whereas the treatment gap encompassed only 5% (n=13). The criteria were the following: 1. Among 18 participants taking no AED, 72% (n=13) had active epilepsy. 2. Among 26 adults on subtherapeutic monotherapy, 46% (n=12) had active epilepsy. 3. Among 48 participants reporting staring spells, 56% (n=27) were treated with carbamazepine or phenytoin. 4. Among 101 female participants aged 14-40years, 23% (n=23) were treated with sodium valproate. 5. Among 67 participants reporting seizure-related injuries, 87% (n=58) had active epilepsy. 6. Among 111 participants with a QOLIE-31 score below 50/100, 77% (n=86) had active epilepsy. Years since first AED treatment (odds ratio: 1.07, 95% CI: 1.03, 1.12) and epileptiform discharges on EEG (odds ratio: 1.95, 95% CI: 1.15, 3.29) were significantly associated with more criteria met. CONCLUSIONS By defining the management gap, subpopulations at greatest need for targeted interventions may be prioritized, including those already taking AEDs.
Collapse
|
16
|
Jost J, Preux PM, Druet-Cabanac M, Ratsimbazafy V. How to reduce the treatment gap for people with epilepsy in resource-limited settings by innovative galenic formulations: A review of the current situation, overview of potential techniques, interests and limits. Epilepsy Res 2016; 119:49-61. [DOI: 10.1016/j.eplepsyres.2015.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2015] [Revised: 08/24/2015] [Accepted: 10/25/2015] [Indexed: 10/22/2022]
|